REST Study on Revosyl® – Real-World Evidence in Hypertension Care In line with its commitment to providing effective and safe therapies for patients with hypertension, Ibn Al Haytham Pharmaceutical Industries proudly conducted the first post-marketing surveillance (PMS) study in Syria on Revosyl® (Perindopril).

The REST study aimed to evaluate the efficacy, safety, and tolerability of Revosyl in the real-life clinical management of essential hypertension. The study included 1,959 patients across various Syrian provinces and was conducted by 141 participating physicians.

Patients received Revosyl in 4 mg or 8 mg doses—either as monotherapy or in combination with other antihypertensives—and were followed over a three-month period.

Results demonstrated a significant reduction in blood pressure as early as the first two visits, with excellent tolerability in the majority of patients. Revosyl proved effective in both newly diagnosed and previously treated patients.

This study confirms that Revosyl, at both 4 mg and 8 mg doses, offers a safe and effective treatment for essential hypertension in routine clinical practice in Syria, with high patient compliance and satisfaction.